Synergistic activity of ALK and mTOR inhibitors for the treatment of NPM-ALK positive lymphoma
Sara Redaelli(University of Milano-Bicocca), Luca Mologni(University of Milano-Bicocca)
Cited by 28
Related Papers
Activity of second‐generation ALK inhibitors against crizotinib‐resistant mutants in an NPM‐ALK model compared to EML4‐ALK
|Cancer Medicine|2015|88
Inhibition of RET tyrosine kinase by SU5416
|Journal of Molecular Endocrinology|2006|54
NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922
|Oncotarget|2015|33